SCHEMBL3655320

SCHEMBL3655320

CCCCOC(=O)NC(C(=O)O)C1CC1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.41
ACHE P22303 7/20 0.40
HRH3 Q9Y5N1 2/20 0.39
ALDH1A1 P00352 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
GAA P10253 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
MMP2 P08253 1/20 0.39
MMP3 P08254 1/20 0.39
MMP9 P14780 1/20 0.39
MMP8 P22894 1/20 0.39
MMP13 P45452 1/20 0.39
RAB9A P51151 2/20 0.39
MAPT P10636 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
NPC1 O15118 1/20 0.38
HPGD P15428 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23160898 0.94 HRH3 (0.40) EPHX1ACHEHRH3SMN1; SMN2GAA
SCHEMBL4683301 0.93 HRH3 (0.42) EPHX1ACHEHRH3SMN1; SMN2GAA
SCHEMBL2456561 0.79 EPHX1 (0.39) EPHX1ACHEHRH3ALDH1A1SMN1; SMN2
SCHEMBL7416590 0.76 EPHX1 (0.48) EPHX1ACHEALDH1A1SMN1; SMN2MAPK1
SCHEMBL6436784 0.76 TSHR (0.44) ALDH1A1GAAMMP2MMP3MMP13
SCHEMBL14263864 0.76 TSHR (0.44) ALDH1A1GAAMMP2MMP3MMP13
SCHEMBL6436779 0.76 TSHR (0.44) ALDH1A1GAAMMP2MMP3MMP13
SCHEMBL24632189 0.76 EPHX1 (0.54) EPHX1ACHESMN1; SMN2GAAMAPK1
SCHEMBL6984792 0.76 ITGB3 (0.42) EPHX1
SCHEMBL2456560 0.76 ITGB3 (0.42) EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3390389-A1 POLYCYCLIC TLR7/8 ANTAGONISTS AND USE THEREOF IN THE TREATMENT OF IMMUNE DISORDERS Merck Patent GmbH (DE) 2018-10-24 EP disclosed
WO-2017106607-A1 POLYCYCLIC TLR7/8 ANTAGONISTS AND USE THEREOF IN THE TREATMENT OF IMMUNE DISORDERS MERCK PATENT GMBH (DE) 2017-06-22 WO disclosed
EP-2234982-A1 SUBSTITUTED HYDANTOINS AS MEK KINASE INHIBITORS F. Hoffmann-La Roche AG (CH) 2010-10-06 EP disclosed
WO-2009080523-A1 SUBSTITUTED HYDANTOINS AS MEK KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-07-02 WO disclosed
WO-2008101840-A1 COMBINATION OF ERLOTINIB AND MEK-INHIBITORS FOR INHIBITING PROLIFERATION OF TUMOR CELLS F. HOFFMANN-LA ROCHE AG (CH) 2008-08-28 WO disclosed